Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Short Interest Update

Key Points

• Genenta Science S.p.A. experienced a significant 74.5% drop in short interest in September, with total shares short falling from 5,500 to 1,400 as of September 15th.
• Institutional investors have been active, with Citadel Advisors LLC purchasing a new stake worth about $46,000, and both Algebris UK Ltd and Allianz SE significantly increasing their holdings.
• As of Wednesday, Genenta Science's shares opened at $3.21, with a one-year low of $2.56 and a high of $7.28, highlighting its volatility in stock performance.

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA - ) was the recipient of a significant decrease in short interest in September. As of September 15th, there was short interest totaling 1,400 shares, a decrease of 74.5% from the August 31st total of 5,500 shares. Based on an average trading volume of 15,600 shares, the days-to-cover ratio is presently 0.1 days. Based on an average trading volume of 15,600 shares, the days-to-cover ratio is presently 0.1 days.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Citadel Advisors LLC purchased a new stake in shares of Genenta Science during the 4th quarter worth approximately $46,000. Algebris UK Ltd boosted its position in Genenta Science by 122.2% during the first quarter. Algebris UK Ltd now owns 100,000 shares of the company's stock worth $368,000 after purchasing an additional 55,000 shares in the last quarter. Finally, Allianz SE grew its holdings in Genenta Science by 126.2% in the first quarter. Allianz SE now owns 233,550 shares of the company's stock valued at $927,000 after purchasing an additional 130,300 shares during the last quarter. 15.13% of the stock is currently owned by institutional investors and hedge funds.

Genenta Science Stock Performance

Shares of NASDAQ GNTA opened at $3.21 on Wednesday. Genenta Science has a one year low of $2.56 and a one year high of $7.28. The company's fifty day moving average is $3.46 and its two-hundred day moving average is $3.76.

Genenta Science Company Profile

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.